肝腎症候群市場規模、佔有率和成長分析：按疾病、療法、藥物類別、給藥途徑、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球肝腎症候群市場價值為 13 億美元，預計到 2033 年將從 2025 年的 13.9 億美元成長至 24.2 億美元，預測期（2026-2033 年）的複合年成長率為 7.1%。

肝腎症候群 (HRS) 市場涵蓋同時出現肝功能衰竭衰竭和腎功能障礙患者的診斷、治療和支持性護理。這種疾病的全球死亡率超過 70%，且加護病房)收治率居高不下。該領域的成長主要受慢性肝病（如酒精性肝硬化和非酒精性脂肪性肝炎）發病率上升以及急性腎損傷病例增加的推動。 HRS 治療藥物的法規核准正在加速市場准入，領先企業正在開發將特利加壓素和白蛋白聯合用於門診透析的綜合治療方案。醫療機構的報告顯示，這些治療方案顯著降低了肝臟移植的需求，從而提高了保險公司的成本效益。此外，某些地區乙型肝炎相關性肝硬化的高發生率也為跨國公司提供了更多市場機會，使其能夠建立本地基地並進行臨床試驗。

全球肝腎綜合症市場成長要素

慢性肝病（包括肝硬化和B型肝炎）的日益普遍，導致易患肝腎綜合症的患者群體不斷擴大。越來越多的高風險患者對治療方案、臨床監測工具和支持性護理服務的需求也隨之增加。隨著醫療系統投入更多資源來應對這些併發症，製藥公司和診斷設備製造商也積極拓展產品線。這些趨勢推動市場持續成長，因為醫療專業人員正在尋求有效策略來預防肝病患者的腎功能衰退。最終，改善患者照護的努力正在推動該領域的創新和投資。

全球肝腎綜合症市場的限制因素

已通過核准的肝腎綜合症藥物價格高昂，對醫療服務提供者和患者都構成重大挑戰，尤其是在保險報銷選擇有限的地區。高昂的價格往往阻礙了這些療法被納入藥品目錄，迫使醫療專業人員優先選擇更實惠的支持性療法，而非昂貴的標靶治療。這種價格敏感度限制了市場滲透率，並減緩了新療法的推廣速度，因為醫療機構需要在有限的預算內尋求經濟可行的解決方案。因此，這些經濟障礙嚴重限制了市場成長，阻礙了創新療法的普及。

肝腎綜合症的全球市場趨勢

全球肝腎症候群市場正呈現出向精準醫療顯著發展的趨勢，其特徵是整合能夠區分此症候群亞型的特定分子生物標記。這項進步使得更早、更個人化的臨床介入成為可能，減少了侵入性診斷程序的需求，並加速了治療決策。多重檢測平台的日益普及為醫療專業人員提供了可操作的見解，並改善了臨床試驗中的患者分層。這一趨勢正在加強腎臟科醫生和肝臟科醫生之間的合作，促進標靶治療方案的引入，最終改變我們治療患者的方式，並改善全球患者的治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肝腎症候群市場規模：依疾病類型分類

• 1型肝腎症候群（HRS-AKI）
• 2 型肝腎症候群 (HRS-NAKI)

全球肝腎症候群市場規模：依治療類型分類

• 血管收縮療法
• 白蛋白療法
• 腎臟替代療法（透析）
• 肝臟移植
• 其他

全球肝腎綜合症市場規模：按藥物類別分類

• 特利加壓素
• 去甲腎上腺素
• Midodrine+Octreotide
• 白蛋白
• 其他

全球肝腎症候群市場規模：依給藥途徑分類

• 靜脈
• 口服
• 皮下

全球肝腎症候群市場規模：依最終用戶分類

• 醫院
• 專業肝臟中心
• 門診部
• 移植中心

全球肝腎綜合症市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房

全球肝腎綜合症市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Mallinckrodt Pharmaceuticals plc
• Baxter International Inc.
• Grifols, SA
• CSL Behring LLC
• Fresenius Medical Care AG
• Ferring Pharmaceuticals A/S
• Octapharma AG
• BioVie Inc.
• Pharmazz, Inc.
• Nikkiso Co., Ltd.
• Terumo Corporation
• Kedrion SpA
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.
• AbbVie Inc.
• Innoviva Specialty Therapeutics, Inc.
• Ocelot Bio, Inc.
• Cumberland Pharmaceuticals Inc.
• SeaStar Medical Holding Corporation
• Zydus Lifesciences Limited

結論與建議

Global Hepatorenal Syndrome Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.39 Billion in 2025 to USD 2.42 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).

The hepatorenal syndrome market encompasses diagnostics, therapeutics, and supportive care for individuals experiencing simultaneous liver failure and kidney dysfunction, a condition associated with over 70% mortality and significant intensive-care admissions globally. Growth in this sector is primarily driven by the increasing incidence of chronic liver diseases, such as alcohol-related cirrhosis and non-alcoholic steatohepatitis, alongside rising events of acute kidney injury. Regulatory approvals for HRS therapies are expediting market entry, leading companies to create bundled treatment options that combine terlipressin and albumin for outpatient dialysis utilization. Evidence from healthcare facilities indicates a notable reduction in liver transplant demands with these treatment regimens, resulting in cost efficiencies for insurers. Additionally, the high prevalence of hepatitis B-related cirrhosis in certain regions fuels market opportunities for multinational corporations to establish local operations and conduct clinical trials.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatorenal Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatorenal Syndrome Market Segments Analysis

Global hepatorenal syndrome market is segmented by disease type, treatment type, drug class, route of administration, end user, distribution channel and region. Based on disease type, the market is segmented into Type 1 Hepatorenal Syndrome (HRS-AKI) and Type 2 Hepatorenal Syndrome (HRS-NAKI). Based on treatment type, the market is segmented into Vasoconstrictor Therapy, Albumin Therapy, Renal Replacement Therapy (Dialysis), Liver Transplantation and Others. Based on drug class, the market is segmented into Terlipressin, Norepinephrine, Midodrine + Octreotide, Albumin and Others. Based on route of administration, the market is segmented into Intravenous, Oral and Subcutaneous. Based on end user, the market is segmented into Hospitals, Specialty Liver Centers, Ambulatory Care Centers and Transplant Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatorenal Syndrome Market

The increasing prevalence of chronic liver diseases, including cirrhosis and hepatitis B, contributes to a larger population susceptible to hepatorenal syndrome. This rise in at-risk patients intensifies the need for therapeutic solutions, clinical monitoring tools, and supportive care services. As healthcare systems allocate more resources to address these complications, pharmaceutical and diagnostic companies are motivated to expand their product offerings. This dynamic fosters continuous growth in the market, as healthcare professionals pursue effective strategies to prevent renal decline in individuals suffering from liver-related conditions. Ultimately, the push for improved patient care drives innovation and investment in this sector.

Restraints in the Global Hepatorenal Syndrome Market

The high cost of approved medications for hepatorenal syndrome presents a considerable challenge for both healthcare providers and patients, especially in areas where reimbursement options are scarce. These elevated prices often discourage the inclusion of these therapies in formularies, prompting healthcare professionals to favor more affordable supportive treatments instead of investing in costly targeted options. This price sensitivity limits market penetration and slows the rate at which new therapies are adopted, as institutions strive to find economical ways to operate within their constrained budgets. As a result, the growth of the market is significantly restricted by these economic hurdles, which impede access to innovative treatment solutions.

Market Trends of the Global Hepatorenal Syndrome Market

The Global Hepatorenal Syndrome market is experiencing a significant trend toward precision medicine, characterized by the integration of specific molecular biomarkers that distinguish between subtypes of the syndrome. This advancement facilitates earlier and more tailored clinical interventions, reducing the need for invasive diagnostic procedures and expediting treatment decisions. The increasing adoption of multiplex testing platforms is empowering healthcare professionals with actionable insights that enhance patient stratification for clinical trials. This trend is fostering greater collaboration between nephrologists and hepatologists while promoting the implementation of targeted therapeutic protocols, ultimately reshaping the treatment landscape and improving outcomes for patients worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hepatorenal Syndrome Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Type 1 Hepatorenal Syndrome (HRS-AKI)
• Type 2 Hepatorenal Syndrome (HRS-NAKI)

Global Hepatorenal Syndrome Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Vasoconstrictor Therapy
• Albumin Therapy
• Renal Replacement Therapy (Dialysis)
• Liver Transplantation
• Others

Global Hepatorenal Syndrome Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Terlipressin
• Norepinephrine
• Midodrine + Octreotide
• Albumin
• Others

Global Hepatorenal Syndrome Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Oral
• Subcutaneous

Global Hepatorenal Syndrome Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Liver Centers
• Ambulatory Care Centers
• Transplant Centers

Global Hepatorenal Syndrome Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Hepatorenal Syndrome Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Drug Class, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mallinckrodt Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmazz, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nikkiso Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innoviva Specialty Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocelot Bio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cumberland Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SeaStar Medical Holding Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations